59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
May 2024 in “Reactions weekly” 8 citations
,
July 2003 in “Journal of the American Geriatrics Society” Venlafaxine may cause paranoid delusions in some patients.
2 citations
,
March 2015 in “Hepatitis Monthly” A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
8 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
June 2026 in “Pharmaceuticals” 5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.
7 citations
,
July 2007 in “Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy” The medication lopinavir-ritonavir may cause severe hair loss.
37 citations
,
October 2006 in “Archives of Biochemistry and Biophysics” A unique gene mutation causes vitamin D-resistant rickets without causing hair loss.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
June 2023 in “International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science” New information shows Valproate may protect the brain and reduce breathing failure risk but can cause liver damage and other side effects, with genetics affecting dosage needs.